A Case of Sigmoid Colon Cancer in which Somatic Pain was Rapidly Alleviated after Panitumumab Administration Despite Tumor Progression

• Shu Yuasa

  Department of Pharmacy; Palliative care team, Nagoya Memorial Hospital, Nagoya, Japan

• Megumi Kabeya

  Department of Pharmacy;Palliative care team, Nagoya Memorial Hospital, Nagoya, Japan

• Ryuichi Furuta

  Department of Medical Oncology

• Satoshi Hib

  Department of Pharmacy

• Chiaki Koga

  Palliative care team, Nagoya Memorial Hospital, Nagoya, Japan

• Seiji Nagao

  Palliative care team, Nagoya Memorial Hospital, Nagoya, Japan

• and Kenji Ina

  Department of Medical Oncology; Palliative care team, Nagoya Memorial Hospital, Nagoya, Japan

 We present a 72-year-old woman with sigmoid colon cancer in whom the somatic pain was alleviated rapidly after the administration of anti-epidermal growth factor antibodies. Our patient had received 4 cycles of FOLFIRI therapy (irinotecan, 5-fluorouracil, and leucovorin) in combination with panitumumab (Pmab) for the treatment of unresectable primary cancer accompanied with multiple liver metastases and peritonitis carcinomatosa. As grade 3 paronychia eventually occurred, chemotherapy was stopped. After recovery of the grade 3 paronychia, Pmab was re-introduced and administered every alternate cycle to reduce the extent of adverse events. The patient had complained of somatic pain in the lower right abdomen just before re-initiating Pmab administration. The pain intensity decreased immediately after the administration of Pmab. On the next day her pain had remarkably alleviated and she was free from pain for a week. This phenomenon was repeatedly observed. After the re-introduction of Pmab, tumor response was evaluated on computed tomography, which showed progressive disease. We demonstrated that Pmab was effective in the alleviation of somatic pain, although the size of the tumors gradually increased.

Ciardiello F, Tortora G. EGFR antagonist in cancer treatment. N Eng J Med 2008; 358: 1160-74. http://dx.doi.org/10.1056/NEJMra0707704

Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2010; 28: 4697-705. http://dx.doi.org/10.1200/JCO.2009.27.4860

Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S. Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. Head Neck Oncol 2010; 2: 3. http://dx.doi.org/10.1186/1758-3284-2-3

Kersten C, Cameronb MG. Cetuximab alleviates neuropathic pain despite tumour progression. BMJ Case Rep 2012; 2012. pii: bcr1220115374. doi: 10.1136/bcr.12.2011.5374

Doi T, Ohtsu A, Tahara M, et al. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol 2009; 14: 307-14. http://dx.doi.org/10.1007/s10147-008-0855-2

Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009; 60: 135-48. http://dx.doi.org/10.1016/j.brainresrev.2008.12.011

Fang M, Wang Y, He QH, et al. Glial cell line-derived neurotropic factor contributes to delayed inflammatory hyperalgesia in adjuvant rat pain model. Neuroscience 2003; 117: 503-12. http://dx.doi.org/10.1016/S0306-4522(02)00958-2

Scolz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells, and glia. Nature Neurosci 2007; 10: 1361-8. http://dx.doi.org/10.1038/nn1992

Andres C, Meyer S, Dina OA, Levine JD, Hucho T. Quantitative automated microscopy (QuAM) elucidates growth factor specific signalling in pain sensitization. Molecular Pain 2010; 6: 98. http://dx.doi.org/10.1186/1744-8069-6-98

Kersten C, Cameronb MG, Mjålandb S. Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain–A case series. Scand J Pain 2013; 4: 3-7. http://dx.doi.org/10.1016/j.sjpain.2012.11.011

• PDF